Palmo-plantar Erythrodysesthesia caused by Liposome-encapsulated Doxorubicin
Authors:
V. Miňovská
Authors‘ workplace:
Dermatovenerologická klinika 1. LF UK, VFN Prahapřednosta doc. MUDr. J. Štork, CSc.
Published in:
Čes-slov Derm, , 2003, No. 4, p. 159-161
Category:
Overview
Palmo-plantar erythrodysesthesia (PPE) is a relatively frequent manifestation of the side-effectsof chemotherapy in the skin. It has a clear-out clinical picture, non-specific histology and unclearpathogenesis. Its course in patients often calls for modification and sometimes interruption ofotherwise effective chemotherapy. There is no specific treatment, however, there has been describedthe possible application of certain drugs in cases of chemotherapeutics with which the risk of PPEis most often connected (doxorubicin, cytarabin, docetaxel, fluorouracil). The author describesa clinical case of PPE upon application of liposome-encapsulated doxorubicin in a patient sufferingfrom ovarial carcinoma.
Key words:
chemotherapy - doxorubicin - side-effects - erythrodysesthesia
Labels
Dermatology & STDs Paediatric dermatology & STDsArticle was published in
Czech-Slovak Dermatology
2003 Issue 4
Most read in this issue
- Granular Parakeratosis
- Palmo-plantar Erythrodysesthesia caused by Liposome-encapsulated Doxorubicin
- Malignant Eccrine Poroma (Eccrine Porocarcinoma)
- Use of the S-100 Protein as a Tumour Marker in Malignant Melanoma